APO Research
Talk to an analyst

APO RESEARCH · REPORT

Multiplex Immunofluorescence (mIF) Technology

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Multiplex Immunofluorescence (mIF) Technology Market Outlook and Growth Opportunities 2026

6 March 2026191 pages

Choose your research edition.

Industry ResearchMultiplex Immunofluorescence (mIF) Technology Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Multiplex Immunofluorescence (mIF) Technology Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Multiplex Immunofluorescence (mIF) Technology Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multiplex Immunofluorescence (mIF) Technology Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Multiplex Immunofluorescence (mIF) Technology Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Multiplex Immunofluorescence (mIF) Technology market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Multiplex Immunofluorescence (mIF) Technology is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Multiplex Immunofluorescence (mIF) Technology is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Multiplex Immunofluorescence (mIF) Technology is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Multiplex Immunofluorescence (mIF) Technology market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Multiplex Immunofluorescence (mIF) Technology market include Eureka Biotech, ICON plc, Discovery Life Sciences, Precision Medicine Group, Terry Technologies, MGI Tech, panovue, Biospective and iCuraDx, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Multiplex Immunofluorescence (mIF) Technology market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Multiplex Immunofluorescence (mIF) Technology and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Multiplex Immunofluorescence (mIF) Technology revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Multiplex Immunofluorescence (mIF) Technology market.

Multiplex Immunofluorescence (mIF) Technology Segment by Company

Eureka Biotech

ICON plc

Discovery Life Sciences

Precision Medicine Group

Terry Technologies

MGI Tech

panovue

Biospective

iCuraDx

Yucebio

Flagship Biosciences

Lanterne Dx (LDX)

Crown Bioscience

Multiplex Immunofluorescence (mIF) Technology Segment by Type

Direct Labeling mIF Technology

TSA-based Amplification mIF Technology

Dual-amplification mIF Technology

Multiplex Immunofluorescence (mIF) Technology Segment by Application

Tumor Immunology Research

Clinical Pathological Diagnosis

Immune Microenvironment Profiling

Other

Multiplex Immunofluorescence (mIF) Technology Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Multiplex Immunofluorescence (mIF) Technology status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Multiplex Immunofluorescence (mIF) Technology key companies, revenue, market share, and recent developments.

3. To split the Multiplex Immunofluorescence (mIF) Technology breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Multiplex Immunofluorescence (mIF) Technology market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Multiplex Immunofluorescence (mIF) Technology significant trends, drivers, influence factors in global and regions.

6. To analyze Multiplex Immunofluorescence (mIF) Technology competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multiplex Immunofluorescence (mIF) Technology market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multiplex Immunofluorescence (mIF) Technology and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multiplex Immunofluorescence (mIF) Technology.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Multiplex Immunofluorescence (mIF) Technology industry.

Chapter 3: Detailed analysis of Multiplex Immunofluorescence (mIF) Technology company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Multiplex Immunofluorescence (mIF) Technology in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Multiplex Immunofluorescence (mIF) Technology in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Multiplex Immunofluorescence (mIF) Technology Industry Trends Table 2. Multiplex Immunofluorescence (mIF) Technology Industry Drivers Table 3. Multiplex Immunofluorescence (mIF) Technology Industry Opportunities and Challenges Table 4. Multiplex Immunofluorescence (mIF) Technology Industry Restraints Table 5. Global Multiplex Immunofluorescence (mIF) Technology Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Multiplex Immunofluorescence (mIF) Technology Revenue Share by Company (2021-2026) Table 7. Global Multiplex Immunofluorescence (mIF) Technology Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Multiplex Immunofluorescence (mIF) Technology Key Company Manufacturing Base & Headquarters Table 9. Global Multiplex Immunofluorescence (mIF) Technology Company, Product Type & Application Table 10. Global Multiplex Immunofluorescence (mIF) Technology Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Multiplex Immunofluorescence (mIF) Technology by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Direct Labeling mIF Technology Table 15. Significant Companies of TSA-based Amplification mIF Technology Table 16. Significant Companies of Dual-amplification mIF Technology Table 17. Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type (2021-2026) Table 21. Global Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Tumor Immunology Research Table 23. Significant Companies of Clinical Pathological Diagnosis Table 24. Significant Companies of Immune Microenvironment Profiling Table 25. Significant Companies of Other Table 26. Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application (2021-2026) Table 30. Global Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application (2027-2032) Table 31. Global Multiplex Immunofluorescence (mIF) Technology Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Region (2021-2026) Table 34. Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Region (2027-2032) Table 36. Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Multiplex Immunofluorescence (mIF) Technology Sales Value Market Share by Country (2021-2026) Table 39. Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Multiplex Immunofluorescence (mIF) Technology Sales Value Market Share by Country (2027-2032) Table 41. Eureka Biotech Company Information Table 42. Eureka Biotech Business Overview Table 43. Eureka Biotech Multiplex Immunofluorescence (mIF) Technology Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Eureka Biotech Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 45. Eureka Biotech Recent Development Table 46. ICON plc Company Information Table 47. ICON plc Business Overview Table 48. ICON plc Multiplex Immunofluorescence (mIF) Technology Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. ICON plc Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 50. ICON plc Recent Development Table 51. Discovery Life Sciences Company Information Table 52. Discovery Life Sciences Business Overview Table 53. Discovery Life Sciences Multiplex Immunofluorescence (mIF) Technology Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Discovery Life Sciences Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 55. Discovery Life Sciences Recent Development Table 56. Precision Medicine Group Company Information Table 57. Precision Medicine Group Business Overview Table 58. Precision Medicine Group Multiplex Immunofluorescence (mIF) Technology Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Precision Medicine Group Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 60. Precision Medicine Group Recent Development Table 61. Terry Technologies Company Information Table 62. Terry Technologies Business Overview Table 63. Terry Technologies Multiplex Immunofluorescence (mIF) Technology Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Terry Technologies Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 65. Terry Technologies Recent Development Table 66. MGI Tech Company Information Table 67. MGI Tech Business Overview Table 68. MGI Tech Multiplex Immunofluorescence (mIF) Technology Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. MGI Tech Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 70. MGI Tech Recent Development Table 71. panovue Company Information Table 72. panovue Business Overview Table 73. panovue Multiplex Immunofluorescence (mIF) Technology Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. panovue Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 75. panovue Recent Development Table 76. Biospective Company Information Table 77. Biospective Business Overview Table 78. Biospective Multiplex Immunofluorescence (mIF) Technology Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Biospective Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 80. Biospective Recent Development Table 81. iCuraDx Company Information Table 82. iCuraDx Business Overview Table 83. iCuraDx Multiplex Immunofluorescence (mIF) Technology Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. iCuraDx Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 85. iCuraDx Recent Development Table 86. Yucebio Company Information Table 87. Yucebio Business Overview Table 88. Yucebio Multiplex Immunofluorescence (mIF) Technology Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Yucebio Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 90. Yucebio Recent Development Table 91. Flagship Biosciences Company Information Table 92. Flagship Biosciences Business Overview Table 93. Flagship Biosciences Multiplex Immunofluorescence (mIF) Technology Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Flagship Biosciences Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 95. Flagship Biosciences Recent Development Table 96. Lanterne Dx (LDX) Company Information Table 97. Lanterne Dx (LDX) Business Overview Table 98. Lanterne Dx (LDX) Multiplex Immunofluorescence (mIF) Technology Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Lanterne Dx (LDX) Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 100. Lanterne Dx (LDX) Recent Development Table 101. Crown Bioscience Company Information Table 102. Crown Bioscience Business Overview Table 103. Crown Bioscience Multiplex Immunofluorescence (mIF) Technology Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Crown Bioscience Multiplex Immunofluorescence (mIF) Technology Product Portfolio Table 105. Crown Bioscience Recent Development Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Multiplex Immunofluorescence (mIF) Technology Product Image Figure 2. Global Multiplex Immunofluorescence (mIF) Technology Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multiplex Immunofluorescence (mIF) Technology Market Size (2021-2032) & (US$ Million) Figure 4. Global Multiplex Immunofluorescence (mIF) Technology Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Direct Labeling mIF Technology Image Figure 8. TSA-based Amplification mIF Technology Image Figure 9. Dual-amplification mIF Technology Image Figure 10. Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Multiplex Immunofluorescence (mIF) Technology Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type (2021-2032) Figure 13. Tumor Immunology Research Image Figure 14. Clinical Pathological Diagnosis Image Figure 15. Immune Microenvironment Profiling Image Figure 16. Other Image Figure 17. Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Multiplex Immunofluorescence (mIF) Technology Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application (2021-2032) Figure 20. Global Multiplex Immunofluorescence (mIF) Technology Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Multiplex Immunofluorescence (mIF) Technology Sales Value (2021-2032) & (US$ Million) Figure 23. North America Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Multiplex Immunofluorescence (mIF) Technology Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Multiplex Immunofluorescence (mIF) Technology Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Multiplex Immunofluorescence (mIF) Technology Sales Value (2021-2032) & (US$ Million) Figure 29. South America Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Multiplex Immunofluorescence (mIF) Technology Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Direct Labeling mIF Technology
  • TSA-based Amplification mIF Technology
  • Dual-amplification mIF Technology
Applications
  • Tumor Immunology Research
  • Clinical Pathological Diagnosis
  • Immune Microenvironment Profiling
  • Other
Companies covered
  • Eureka Biotech
  • ICON plc
  • Discovery Life Sciences
  • Precision Medicine Group
  • Terry Technologies
  • MGI Tech
  • panovue
  • Biospective
  • iCuraDx
  • Yucebio
  • Flagship Biosciences
  • Lanterne Dx (LDX)
  • Crown Bioscience

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Multiplex Immunofluorescence (mIF) Technology Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Multiplex Immunofluorescence (mIF) Technology Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Multiplex Immunofluorescence (mIF) Technology Market Dynamics
  1. 2.1 Multiplex Immunofluorescence (mIF) Technology Industry Trends
  2. 2.2 Multiplex Immunofluorescence (mIF) Technology Industry Drivers
  3. 2.3 Multiplex Immunofluorescence (mIF) Technology Industry Opportunities and Challenges
  4. 2.4 Multiplex Immunofluorescence (mIF) Technology Industry Restraints
3 Multiplex Immunofluorescence (mIF) Technology Market by Company
  1. 3.1 Global Multiplex Immunofluorescence (mIF) Technology Company Revenue Ranking in 2025
  2. 3.2 Global Multiplex Immunofluorescence (mIF) Technology Revenue by Company (2021-2026)
  3. 3.3 Global Multiplex Immunofluorescence (mIF) Technology Company Ranking (2024-2026)
  4. 3.4 Global Multiplex Immunofluorescence (mIF) Technology Company Manufacturing Base and Headquarters
  5. 3.5 Global Multiplex Immunofluorescence (mIF) Technology Company Product Type and Application
  6. 3.6 Global Multiplex Immunofluorescence (mIF) Technology Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Multiplex Immunofluorescence (mIF) Technology Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Multiplex Immunofluorescence (mIF) Technology Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Multiplex Immunofluorescence (mIF) Technology Market by Type
  1. 4.1 Multiplex Immunofluorescence (mIF) Technology Type Introduction
  2. 4.1.1 Direct Labeling mIF Technology
  3. 4.1.2 TSA-based Amplification mIF Technology
  4. 4.1.3 Dual-amplification mIF Technology
  5. 4.2 Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Type
  6. 4.2.1 Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Type (2021-2032)
  8. 4.2.3 Global Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type (2021-2032)
5 Multiplex Immunofluorescence (mIF) Technology Market by Application
  1. 5.1 Multiplex Immunofluorescence (mIF) Technology Application Introduction
  2. 5.1.1 Tumor Immunology Research
  3. 5.1.2 Clinical Pathological Diagnosis
  4. 5.1.3 Immune Microenvironment Profiling
  5. 5.1.4 Other
  6. 5.2 Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Application
  7. 5.2.1 Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Application (2021-2032)
  9. 5.2.3 Global Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application (2021-2032)
6 Multiplex Immunofluorescence (mIF) Technology Regional Value Analysis
  1. 6.1 Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Region (2021-2032)
  3. 6.2.1 Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Region: 2021-2026
  4. 6.2.2 Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Multiplex Immunofluorescence (mIF) Technology Sales Value (2021-2032)
  7. 6.3.2 North America Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Multiplex Immunofluorescence (mIF) Technology Sales Value (2021-2032)
  10. 6.4.2 Europe Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Multiplex Immunofluorescence (mIF) Technology Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Multiplex Immunofluorescence (mIF) Technology Sales Value (2021-2032)
  16. 6.6.2 South America Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Multiplex Immunofluorescence (mIF) Technology Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Country, 2025 VS 2032
7 Multiplex Immunofluorescence (mIF) Technology Country-level Value Analysis
  1. 7.1 Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Country (2021-2032)
  3. 7.2.1 Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Country (2021-2026)
  4. 7.2.2 Global Multiplex Immunofluorescence (mIF) Technology Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Multiplex Immunofluorescence (mIF) Technology Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Multiplex Immunofluorescence (mIF) Technology Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eureka Biotech
  2. 8.1.1 Eureka Biotech Company Information
  3. 8.1.2 Eureka Biotech Business Overview
  4. 8.1.3 Eureka Biotech Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eureka Biotech Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  6. 8.1.5 Eureka Biotech Recent Developments
  7. 8.2 ICON plc
  8. 8.2.1 ICON plc Company Information
  9. 8.2.2 ICON plc Business Overview
  10. 8.2.3 ICON plc Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  11. 8.2.4 ICON plc Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  12. 8.2.5 ICON plc Recent Developments
  13. 8.3 Discovery Life Sciences
  14. 8.3.1 Discovery Life Sciences Company Information
  15. 8.3.2 Discovery Life Sciences Business Overview
  16. 8.3.3 Discovery Life Sciences Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Discovery Life Sciences Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  18. 8.3.5 Discovery Life Sciences Recent Developments
  19. 8.4 Precision Medicine Group
  20. 8.4.1 Precision Medicine Group Company Information
  21. 8.4.2 Precision Medicine Group Business Overview
  22. 8.4.3 Precision Medicine Group Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Precision Medicine Group Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  24. 8.4.5 Precision Medicine Group Recent Developments
  25. 8.5 Terry Technologies
  26. 8.5.1 Terry Technologies Company Information
  27. 8.5.2 Terry Technologies Business Overview
  28. 8.5.3 Terry Technologies Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Terry Technologies Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  30. 8.5.5 Terry Technologies Recent Developments
  31. 8.6 MGI Tech
  32. 8.6.1 MGI Tech Company Information
  33. 8.6.2 MGI Tech Business Overview
  34. 8.6.3 MGI Tech Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  35. 8.6.4 MGI Tech Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  36. 8.6.5 MGI Tech Recent Developments
  37. 8.7 panovue
  38. 8.7.1 panovue Company Information
  39. 8.7.2 panovue Business Overview
  40. 8.7.3 panovue Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  41. 8.7.4 panovue Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  42. 8.7.5 panovue Recent Developments
  43. 8.8 Biospective
  44. 8.8.1 Biospective Company Information
  45. 8.8.2 Biospective Business Overview
  46. 8.8.3 Biospective Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Biospective Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  48. 8.8.5 Biospective Recent Developments
  49. 8.9 iCuraDx
  50. 8.9.1 iCuraDx Company Information
  51. 8.9.2 iCuraDx Business Overview
  52. 8.9.3 iCuraDx Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  53. 8.9.4 iCuraDx Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  54. 8.9.5 iCuraDx Recent Developments
  55. 8.10 Yucebio
  56. 8.10.1 Yucebio Company Information
  57. 8.10.2 Yucebio Business Overview
  58. 8.10.3 Yucebio Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Yucebio Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  60. 8.10.5 Yucebio Recent Developments
  61. 8.11 Flagship Biosciences
  62. 8.11.1 Flagship Biosciences Company Information
  63. 8.11.2 Flagship Biosciences Business Overview
  64. 8.11.3 Flagship Biosciences Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Flagship Biosciences Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  66. 8.11.5 Flagship Biosciences Recent Developments
  67. 8.12 Lanterne Dx (LDX)
  68. 8.12.1 Lanterne Dx (LDX) Company Information
  69. 8.12.2 Lanterne Dx (LDX) Business Overview
  70. 8.12.3 Lanterne Dx (LDX) Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Lanterne Dx (LDX) Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  72. 8.12.5 Lanterne Dx (LDX) Recent Developments
  73. 8.13 Crown Bioscience
  74. 8.13.1 Crown Bioscience Company Information
  75. 8.13.2 Crown Bioscience Business Overview
  76. 8.13.3 Crown Bioscience Multiplex Immunofluorescence (mIF) Technology Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Crown Bioscience Multiplex Immunofluorescence (mIF) Technology Product Portfolio
  78. 8.13.5 Crown Bioscience Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst